About BridgeBio
BridgeBio is a company based in Palo Alto (United States) founded in 2015 by Neil Kumar and Frank McCormick was acquired by Bristol-Myers Squibb in May 2022. BridgeBio has raised $434.2 million across 5 funding rounds from investors including KKR, AIG and Hercules Capital. The company has 730 employees as of December 31, 2024. BridgeBio has completed 1 acquisition, including Eidos Therapeutics. BridgeBio offers products and services including Attruby and Nulibry. BridgeBio operates in a competitive market with competitors including Insitro, Moderna, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Palo Alto, United States
- Employees 730 as on 31 Dec, 2024
- Founders Neil Kumar, Frank McCormick
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Bridgebio Pharma, Inc.
-
Annual Revenue
$221.9 M (USD)2285.27as on Dec 31, 2024
-
Net Profit
-$535.76 M (USD)16.7as on Dec 31, 2024
-
EBITDA
-$571.29 M (USD)3.65as on Dec 31, 2024
-
Total Equity Funding
$434.2 M (USD)
in 5 rounds
-
Latest Funding Round
$200 M (USD), Post-IPO
Apr 30, 2024
-
Investors
KKR
& 19 more
-
Employee Count
730
as on Dec 31, 2024
- Investments & Acquisitions
-
Acquired by
Bristol-Myers Squibb
(May 12, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of BridgeBio
BridgeBio is a publicly listed company on the NASDAQ with ticker symbol BBIO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of BridgeBio
BridgeBio offers a comprehensive portfolio of products and services, including Attruby and Nulibry.
Treatment for specific genetic diseases through targeted therapy.
Medicine for genetic conditions affecting patient health.
People of BridgeBio
Unlock access to complete
Leadership Team
82 people
Software Development Team
28 people
Operations Team
23 people
Sales and Marketing
15 people
Human Resources and Administration
12 people
Finance and Accounting
10 people
Senior Team
8 people
Legal and Compliance
7 people
Unlock access to complete
Funding Insights of BridgeBio
BridgeBio has successfully raised a total of $434.2M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $200 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in BridgeBio
BridgeBio has secured backing from 20 investors, including institutional and venture fund investors. Prominent investors backing the company include KKR, AIG and Hercules Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are invested in by this private equity firm.
|
Locked | Locked | Locked | |
|
Private investment firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked |
Investor details for BridgeBio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BridgeBio
BridgeBio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Eidos Therapeutics.
Investment portfolio details for BridgeBio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Small-molecule treatments for transthyretin amyloidosis are developed.
|
Locked | Locked | 2016 | Locked |
Complete acquisition details for BridgeBio
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - BridgeBio
Detailed financials for BridgeBio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bridgebio Comparisons
Peer comparison for BridgeBio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BridgeBio
BridgeBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, Moderna, ATAI, Forge Biologics and Spark Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
Detailed competitors of BridgeBio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bridgebio
Complete news archive for BridgeBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BridgeBio
BridgeBio was founded in 2015 and raised its 1st funding round 2 years after it was founded.
BridgeBio is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Neil Kumar is the current CEO of BridgeBio. They have also founded this company.
BridgeBio is a funded company, having raised a total of $434.2M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at BridgeBio is 730.
Annual revenue of BridgeBio is $221.9M as on Dec 31, 2024.
The company was founded in 2015 in Palo Alto, United States, and operates in the biotechnology sector focused on genetic diseases. Opportunities for therapeutic intervention are identified by mapping genetic disease landscapes. Drug candidates, such as PTCH1-inhibitors for Gorlin syndrome and S1P-lyase inhibitors for Darier and Hailey-Hailey diseases, are advanced through clinical development. Operations emphasize precision medicine approaches to address unmet needs in rare genetic conditions.
BridgeBio's top competitors include Moderna, Spark Therapeutics and Forge Biologics.
BridgeBio offers Attruby and Nulibry.
Yes, BridgeBio is publicly traded on NASDAQ under the ticker symbol BBIO.
BridgeBio has made 1 acquisition, including Eidos Therapeutics.
BridgeBio has 20 investors. Key investors include KKR, AIG, Hercules Capital, Citadel, and Bristol-Myers Squibb.
The ticker symbol of BridgeBio is BBIO on NASDAQ.